IgM to phosphatidylcholine in multiple sclerosis patients: from the diagnosis to the treatment
Isabel Sánchez-Vera1, Esther Escudero1, Úrsula Muñoz1
1Facultad de Medicina, Instituto de Medicina Molecular Aplicada (IMMA), Universidad San Pablo-CEU, CEU Universities, Madrid, Spain.
Abstract:
Multiple sclerosis (MS) is a demyelinating and neurodegenerative disease of the central nervous system. It affects young people, and a considerable percentage of patients need the help of a wheelchair in 15 years of evolution. Currently, there is not a specific technique for the diagnosis of MS. The detection of oligoclonal IgG bands (OIgGBs) is the most sensitive assay for it, but it is not standardizable, only reference laboratories develop it, and uses cerebrospinal fluid. To obtain this sample, a lumbar puncture is necessary, an invasive proceeding with important side effects. It is important to develop and implement standard assays to obtain a rapid diagnosis because the earlier the treatment, the better the evolution of the disease. There are numerous modifying disease therapies, which delay the progression of the disease, but they have important side effects, and a considerable percentage of patients give up the treatment. In addition, around 40% of MS patients do not respond to the therapy and the disease progresses. Numerous researches have been focused on the characterization of predictive biomarkers of response to treatment, in order to help physicians to decide when to change to a second-line treatment, and then the best therapeutic option. Here, we review the new biomarkers for the diagnosis and response to treatment in MS. We draw attention in a new assay, the detection of serum IgM to phosphatidylcholine, that showed a similar sensitivity as OIgGBs and predicts the response to disease modifying treatments.
Insights
Diagnosing multiple sclerosis (MS) can be improved with new biomarkers. A novel assay detecting serum IgM to phosphatidylcholine shows promise for both diagnosis and predicting treatment response in MS patients.
Area of Science:
- Neurology
- Immunology
- Biomarker Discovery
Background:
- Multiple sclerosis (MS) is a central nervous system disorder causing demyelination and neurodegeneration, often impacting young adults.
- Current MS diagnosis lacks specificity, relying on invasive lumbar punctures for oligoclonal IgG band detection, which is not standardized.
- Effective disease-modifying therapies exist but have side effects, and a significant portion of patients do not respond, necessitating treatment adjustments.
Purpose of the Study:
- To review novel biomarkers for diagnosing MS.
- To identify biomarkers that predict patient response to disease-modifying treatments.
- To highlight a new diagnostic and predictive assay for MS.
Main Methods:
- Review of current literature on MS diagnostic and prognostic biomarkers.
- Evaluation of the sensitivity and specificity of novel biomarkers compared to existing methods.
- Focus on serum IgM to phosphatidylcholine as a potential diagnostic and predictive marker.
Main Results:
- The detection of oligoclonal IgG bands (OIgGBs) is a sensitive but non-standardized diagnostic marker requiring cerebrospinal fluid.
- Serum IgM to phosphatidylcholine shows comparable sensitivity to OIgGBs for MS diagnosis.
- This novel biomarker also demonstrates predictive value for response to disease-modifying treatments in MS patients.
Conclusions:
- Development of standardized, non-invasive assays is crucial for early MS diagnosis and timely treatment initiation.
- Serum IgM to phosphatidylcholine represents a promising biomarker for both MS diagnosis and predicting treatment efficacy.
- Further research and implementation of this assay could significantly improve MS patient management and outcomes.
More Related Videos
08:40Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis
Published on: February 28, 2021
04:55A Stably Established Two-Point Injection of Lysophosphatidylcholine-Induced Focal Demyelination Model in Mice
Published on: May 11, 2022
